AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased an additional 5,000 shares of ACUT stock in the open market. This acquisition increases Cerrone's total holdings to 4,915,759 shares of the company.
AccuStem Sciences (OTCQB: ACUT), un'azienda in fase clinica specializzata in diagnostica per il miglioramento degli esiti dei pazienti oncologici, ha annunciato che il Presidente del Consiglio, Gabriele Cerrone, ha acquistato sul mercato aperto ulteriori 5.000 azioni di ACUT. Questo acquisto porta la quota totale di Cerrone a 4.915.759 azioni della società.
AccuStem Sciences (OTCQB: ACUT), una compañía en etapa clínica enfocada en el diagnóstico para mejorar los resultados en pacientes con cáncer, anunció que el Presidente del Consejo, Gabriele Cerrone, ha adquirido en el mercado abierto 5,000 acciones adicionales de ACUT. Esta compra eleva la participación total de Cerrone a 4,915,759 acciones de la empresa.
AccuStem Sciences (OTCQB: ACUT)는 암 환자 치료 결과에 중점을 둔 임상 단계 진단 회사로, 이사회 의장 가브리엘레 체로네가 공개 시장에서 추가로 5,000주의 ACUT 주식을 매입했다고 발표했습니다. 이번 매입으로 체로네 의장의 총 보유 주식 수는 4,915,759주가 되었습니다.
AccuStem Sciences (OTCQB : ACUT), une société de diagnostic en phase clinique axée sur les résultats des patients atteints de cancer, a annoncé que le président du conseil d'administration, Gabriele Cerrone, a acheté 5 000 actions supplémentaires d'ACUT sur le marché libre. Cette acquisition porte la participation totale de Cerrone à 4 915 759 actions de la société.
AccuStem Sciences (OTCQB: ACUT), ein Diagnostikunternehmen in der klinischen Phase mit Fokus auf die Behandlungsergebnisse von Krebspatienten, gab bekannt, dass der Vorstandsvorsitzende Gabriele Cerrone weitere 5.000 Aktien von ACUT am offenen Markt erworben hat. Dieser Erwerb erhöht Cerrones Gesamtbestand auf 4.915.759 Aktien des Unternehmens.
- Chairman's insider buying demonstrates management confidence
- Significant insider ownership with Chairman holding nearly 5 million shares
- None.
LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 5,000 ACUT shares in the open market. This brings his total holding to 4,915,759 shares.
About AccuStem
AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making.
For more information, please visit www.accustem.com.
Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com
FAQ
How many ACUT shares did AccuStem's Chairman purchase in April 2025?
What is the total number of shares held by AccuStem's Chairman after the recent purchase?
When did AccuStem's Chairman increase his stake in the company?
What does the Chairman's share purchase indicate about ACUT stock?
